-A Phase 2a study of BAER-101 in epilepsy is planned to initiate in 2024MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) --...
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Aug. 01, 2023 (GLOBE...
VANCOUVER BC / ACCESSWIRE / August 1, 2023 / EMPOWER CLINICS INC. (CSE:EPW)(OTC PINK:EPWCF) ("Empower" or the "Company") announces today,...
PRINCETON, NJ / ACCESSWIRE / July 31, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical...
After the completion of local regulatory approvals, Aytu anticipates exporting to Medomie both of its novel, orally disintegrating, extended-release tablets...
Multiple Research Studies Are In Official Application Stage For EPW Curesearch Sites Covering Numerous Protocols And SpecialtiesVANCOUVER, BC / ACCESSWIRE...
SAN DIEGO and SUZHOU and SHANGHAI, China, July 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company",...
Garching / Munich, Germany and Indianapolis, IN, USA, July 31, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading...
GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading...
CINCINNATI, July 31, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology...
NEW YORK, July 31, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc. (NASDAQ: MEDS) (“TRxADE”), a pharmaceutical exchange platform provider, today...
- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events (HAEs) Including Neutropenia, Anemia, and...
Transaction and reduction in operating expenses enhance Mustang’s cash positionWORCESTER, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc....
Patent Filing Follows Year of Preclinical Research, Academic PublicationVANCOUVER, British Columbia, July 31, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings...
Conference call to be held Tuesday, August 1, 2023, at 8:30 AM ETNEW YORK, July 31, 2023 (GLOBE NEWSWIRE) --...
Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Spero to receive $30...
Webinar Being Held on August 8, 2023 at 12:00 p.m. Eastern TimeSAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Crinetics...
CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on...
Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design and developmentInstaDeep to operate as...